5-MeO-DMT therapy uses a structured programme built around a 20–45 minute ceremony — preparation sessions, the administration of 5-methoxy-N,N-dimethyltryptamine in a supervised setting, and structured integration work in the weeks that follow. The pharmacological experience is one of the most intense known: complete ego dissolution within seconds of inhalation, with no visual narrative content and no story to decode afterward. The therapy is not the experience. The experience is the event at the centre. What it produces, for whom, and under what conditions are the questions worth addressing before anything else.
5-MeO-DMT therapy at Transcend in Vancouver costs $600–$1,500 CAD and includes a 20–45 minute ceremony with full facilitation, preparation, and access to integration coaching. Absolute contraindications include SSRIs, SNRIs, MAOIs, antipsychotics, lithium, cardiovascular conditions, and any personal or family history of psychosis or schizophrenia. The therapy is not a lighter version of ibogaine because the ceremony is shorter — shorter and easier are not the same thing. The integration period, not the experience itself, determines whether lasting change results.
What 5-MeO-DMT therapy is — and what it is not
5-MeO-DMT therapy refers to a structured programme — not just the experience. The ceremony at its centre lasts 20–45 minutes of active pharmacological effect. What surrounds it is what distinguishes therapy from a single administration: intake and medical screening, preparation work that establishes the person's state before ceremony, the supervised experience itself, and structured integration support in the weeks following.
The compound — 5-methoxy-N,N-dimethyltryptamine — can be drawn from the parotoid gland secretion of the Incilius alvarius toad (formerly Bufo alvarius) or synthesised in a laboratory. The active compound is chemically identical. At Transcend, we use synthetic 5-MeO-DMT. Wild toad collection raises conservation concerns — the Sonoran Desert toad is already under pressure from habitat loss and collection for ceremonial use — and synthetic production allows for more consistent dosing.
5-MeO-DMT therapy is not a clinical trial programme. It is not a replacement for conventional mental health treatment. It is not appropriate for everyone who requests it. And it is not a lighter version of ibogaine because the ceremony is shorter — a misunderstanding worth addressing before someone makes a decision based on it.
5-MeO-DMT is shorter than ibogaine. It is not easier. The intensity of complete ego dissolution in 20–45 minutes produces its own demands, and the absence of narrative content makes integration harder for many people, not simpler. There is nothing to decode after a 5-MeO-DMT ceremony. There is the encounter with the complete dissolution of self, and then the return — and integrating that encounter into ordinary life requires a different kind of work than processing biographical content from ibogaine. For a fuller comparison, see the post on what a bufo ceremony involves.
How 5-MeO-DMT works in the brain
5-MeO-DMT is a full agonist at the 5-HT1A serotonin receptor — the primary mechanism through which it produces its effects. This receptor profile is distinct from psilocybin and LSD, which act primarily through 5-HT2A receptors. The difference matters pharmacologically: 5-HT1A agonism produces a different pattern of effects, including near-total suppression of activity in the default mode network — the brain's self-referential processing system.
The default mode network is the neural architecture of the sense of self: involved in autobiographical memory, self-referential thought, and the continuous narrative we experience as identity. 5-MeO-DMT suppresses DMN activity to a degree that most people experience as the complete dissolution of that sense of self. Neuroimaging studies have documented this suppression directly.
The proposed therapeutic mechanism: when the architecture of self-referential processing is temporarily suspended, the entrenched patterns it maintains — the loops of rumination, rigidly held self-concept, and habituated avoidance — may become more accessible to change. The integration period is when that accessibility is either used or not.
For a detailed account of the neuroscience, see what 5-MeO-DMT does to the brain.
What the current evidence shows
The evidence base for 5-MeO-DMT in humans is less developed than what exists for ibogaine or psilocybin. What exists is consistent in direction.
A 2019 survey study published in Frontiers in Psychology examined 362 individuals who had used 5-MeO-DMT in naturalistic settings. Respondents reported significant reductions in depression, anxiety, and post-traumatic stress symptoms in the weeks following. The strength of the mystical experience — assessed using validated scales — was the strongest predictor of positive outcome. The study was observational and self-selected; it does not meet the evidentiary standard of a randomised controlled trial.
A 2018 study published in Psychopharmacology documented improvements in self-rated wellbeing and life satisfaction following a group 5-MeO-DMT session, persisting at four-week follow-up. The same limitations apply: observational, no control group.
Anyone presenting this observational data as equivalent to controlled trial evidence is overstating it. Anyone dismissing it entirely because it lacks RCTs is ignoring a consistent signal. The honest position: the direction is clear and the evidence is preliminary. For context on the ibogaine evidence base — which is further along the clinical research pipeline — see the overview of ibogaine therapy in Canada.
Who may benefit from 5-MeO-DMT therapy
Based on observational evidence and practitioner reports — not controlled trials — the populations most frequently seeking 5-MeO-DMT therapy and reporting meaningful outcomes include:
- People with treatment-resistant depression who have not found adequate relief through conventional approaches and for whom psilocybin or ketamine have not been effective or available
- People working with PTSD — particularly those for whom narrative-based approaches in therapy have been unproductive or retraumatising
- People dealing with existential distress, grief, or questions of meaning and identity rather than a specific psychiatric diagnosis
- People who have completed an ibogaine ceremony and full integration cycle and are using 5-MeO-DMT as a complementary practice
- People with a stable foundation — no active psychiatric crisis, no contraindicated medications — approaching the work from preparation rather than desperation
Who 5-MeO-DMT therapy does not help: people in acute psychiatric crisis, people taking contraindicated medications who cannot safely taper, people with a history of psychosis, and people whose primary motivation is a specific experience or insight. The medicine does not accommodate that last intention well. People who arrive expecting a particular revelation tend to find the absence of narrative content the most disorienting aspect of what occurs.
Who cannot proceed — absolute contraindications
The following conditions are absolute contraindications for 5-MeO-DMT therapy. No case is an exception.
SSRIs and SNRIs. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors must be fully cleared before any 5-MeO-DMT ceremony. The risk is serotonin syndrome — a potentially fatal condition. This is not a preference to weigh. It is an absolute contraindication. Any provider conducting 5-MeO-DMT ceremony for someone still on SSRIs or SNRIs is not operating safely.
MAOIs. Monoamine oxidase inhibitors are contraindicated through the same serotonergic mechanism. Ayahuasca contains harmala alkaloids that act as MAOIs; sufficient time must pass between ayahuasca use and 5-MeO-DMT ceremony. The timing and sequencing issues are covered in the comparison of ayahuasca and ibogaine.
Antipsychotics and lithium. Both are contraindicated. Lithium in combination with serotonergic compounds carries seizure risk. Most antipsychotics carry QT prolongation risk in combination with 5-MeO-DMT.
Cardiovascular conditions. Pre-existing cardiac arrhythmias, documented QT prolongation, and recent myocardial infarction are contraindications. Medical screening including an EKG is required before any ceremony.
Personal or family history of psychosis or schizophrenia.5-MeO-DMT is contraindicated for anyone with a personal history of psychosis, schizophrenia-spectrum disorder, or a first-degree relative with schizophrenia. The compound's mechanism can trigger psychotic breaks in susceptible individuals. There is no dose that removes this risk. The psychiatric history assessment in intake exists specifically to identify it.
Pregnancy. 5-MeO-DMT therapy is not appropriate during pregnancy.
Someone in acute psychiatric crisis — regardless of motivation — is not an appropriate candidate for ceremony. The experience amplifies what is present. Entering it in a state of acute instability does not produce stability. We tell people this directly and without softening it.
What a legitimate programme includes
A structured 5-MeO-DMT therapy programme includes more than the ceremony. At minimum:
Medical screening. A medical history review, EKG and cardiovascular assessment, review of all current medications, and psychiatric history assessment. This is required before any ceremony date is confirmed. It is not bureaucracy — it is how candidacy is established.
Preparation.At least one preparation session before ceremony. The purpose is not to rehearse the experience — it cannot be rehearsed — but to clarify intention, establish the person's current state, and surface anything in intake or psychiatric history requiring further evaluation.
Facilitation throughout the ceremony. A trained facilitator must be present throughout the 20–45 minute active experience. Participants may become non-verbal, require physical grounding, or have difficulty returning to ordinary verbal communication for some time after the peak. A ceremony without a facilitator physically present is an unsupported administration of a pharmacologically extreme compound.
Recovery period. Most people require 45–90 minutes to return to ordinary verbal functioning after the peak. The hours following ceremony are part of the programme, not optional rest.
Access to integration support. The weeks following ceremony are the period in which integration determines whether the experience produces anything lasting.
At Transcend in Vancouver, 5-MeO-DMT ceremony costs $600–$1,500 CAD. This covers pre-ceremony medical screening, facilitation throughout the active experience, and the recovery period. Integration coaching is available separately at $150–$300 CAD per 60–90 minute session. For a full overview of how a 5-MeO-DMT retreat programme is structured, including what to expect over the full programme period, see the programme overview.
Providers charging significantly below this range are removing something from the list above. The cost of trained facilitation, medical screening, and an appropriate recovery environment is real. A $200 5-MeO-DMT ceremony is not a bargain.
The integration period
The ceremony produces an encounter with the complete dissolution of the sense of self. What happens after — in the hours, days, and weeks following — is where the therapy either takes hold or does not.
Unlike ibogaine, 5-MeO-DMT produces no narrative content to decode. There are no specific memories, no identifiable themes, no story to process. What arrives instead is a shift — in some people profound, in others subtle — in the relationship between the person and their ordinary self-referential patterns. That shift does not automatically translate into sustained change. Integration is the work of making it do so.
The people who see the least durable results from 5-MeO-DMT therapy are the ones who return immediately to the environment, relationships, and unaddressed conditions that produced the presenting problem. The ceremony opens something. What is done in that opening — the deliberate attention to what shifted and why, the structural changes in daily life, the ongoing engagement with integration support — determines the outcome.
At Transcend, integration coaching is structured around 60–90 minute sessions at $150–$300 CAD per session, with packages of three or more available. A practical baseline for 5-MeO-DMT integration is 3–5 sessions in the six weeks following ceremony. Unlike ibogaine's noribogaine metabolite — which sustains elevated neuroplasticity for weeks to months — 5-MeO-DMT's integration window is defined more by psychological readiness and available support than by pharmacology. That window can still close. Returning unchanged to unchanged conditions typically closes it.
If you are considering 5-MeO-DMT therapy and want to begin the screening process, the application starts here. No ceremony date is confirmed before medical screening establishes candidacy. We respond to every application within 2–3 business days.
Frequently Asked Questions
What is 5-MeO-DMT therapy?
5-MeO-DMT therapy is a structured programme using 5-methoxy-N,N-dimethyltryptamine within a framework of preparation, supervised ceremony, and integration support. The active experience produces complete ego dissolution in 20–45 minutes. The therapeutic structure around it — intake, medical screening, preparation, facilitation, and integration — is what distinguishes therapy from unstructured administration of the compound.
Is 5-MeO-DMT therapy the same as a bufo ceremony?
The compound is the same or equivalent. Bufo ceremony uses 5-MeO-DMT drawn from the parotoid secretion of the Incilius alvarius toad; most current therapeutic programmes use synthetic 5-MeO-DMT, which is chemically identical. The term “bufo ceremony” carries specific ceremonial context. “5-MeO-DMT therapy” refers more broadly to the therapeutic programme context. At Transcend, the same screening requirements and facilitation structure apply regardless of terminology.
How long does 5-MeO-DMT therapy take from start to finish?
The active ceremony lasts 20–45 minutes. Recovery to ordinary verbal functioning takes 45–90 minutes. The full on-site programme — screening, preparation, ceremony, and recovery — spans 1–2 days. Integration coaching following ceremony typically extends 4–6 weeks. The programme is not the ceremony. The ceremony is the event at the centre of a process that begins in intake and ends when integration work is complete.
Who is not appropriate for 5-MeO-DMT therapy?
Absolute contraindications include: current SSRIs or SNRIs without a completed supervised taper; any current or recent MAOI use including ayahuasca; lithium; antipsychotics; personal or family history of psychosis or schizophrenia-spectrum disorder; significant cardiac arrhythmia or documented QT prolongation; and pregnancy. Someone in acute psychiatric crisis is not an appropriate candidate regardless of motivation. If any of these apply, 5-MeO-DMT therapy is not available at this time at any responsible provider.
How much does 5-MeO-DMT therapy cost in Vancouver?
At Transcend in Vancouver, BC, 5-MeO-DMT ceremony costs $600–$1,500 CAD. This covers medical screening, facilitation throughout the active experience, and the recovery period. Integration coaching is $150–$300 CAD per 60–90 minute session, available separately. The range reflects individual differences in what a complete programme requires. Providers charging significantly below this range are not being generous — the cost of proper facilitation, medical screening, and an appropriate environment is real.
What does the research say about 5-MeO-DMT therapy for depression?
The most cited published study — a 2019 survey of 362 naturalistic users published in Frontiers in Psychology — documented self-reported reductions in depression and anxiety in the weeks following 5-MeO-DMT use. The findings were correlational and self-reported. Anyone presenting this as definitive clinical evidence is overstating it. Anyone dismissing it because it lacks a control group is ignoring a consistent signal. The direction is clear; the evidentiary base is preliminary.
Is 5-MeO-DMT legal in Canada?
5-MeO-DMT is a controlled substance in Canada under Schedule III of the Controlled Drugs and Substances Act. Its legal status differs from ibogaine, which is not listed under the CDSA and is not explicitly prohibited in Canada. Providers in Canada should be transparent about their legal context. Medical screening is required regardless of legal status — the contraindications are pharmacological, not jurisdictional.
How does 5-MeO-DMT therapy differ from ibogaine therapy?
The mechanisms, durations, and appropriate conditions differ substantially. Ibogaine acts across multiple receptor systems simultaneously — including opioid receptors — has the strongest evidence base for opioid dependence and treatment-resistant PTSD, and requires an on-site physician plus continuous cardiac ECG monitoring throughout a 12–24 hour ceremony. 5-MeO-DMT acts primarily through the 5-HT1A receptor, produces complete ego dissolution in 20–45 minutes with no narrative content, and carries a different contraindication profile. Neither is a lighter version of the other. They are different medicines appropriate for different conditions, with different integration demands.